Estrogen and progesterone receptors have distinct roles in the establishment of the hyperplastic phenotype in PR-A transgenic mice

Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our...

Full description

Saved in:
Bibliographic Details
Published inBreast cancer research : BCR Vol. 11; no. 5; p. R72
Main Authors Simian, Marina, Bissell, Mina J, Barcellos-Hoff, Mary Helen, Shyamala, Gopalan
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 01.01.2009
National Library of Medicine - MEDLINE Abstracts
BioMed Central
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFbeta1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFbeta1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFbeta1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype.
AbstractList Introduction Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. Methods We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGF[beta]1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. Results The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGF[beta]1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. Conclusions These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGF[beta]1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype.
INTRODUCTION: Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. METHODS: We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFβ1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. RESULTS: The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFβ1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. CONCLUSIONS: These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFβ1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype.
Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFbeta1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFbeta1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFbeta1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype.
Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFbeta1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFbeta1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFbeta1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype.
INTRODUCTIONExpression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. METHODSWe subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFbeta1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. RESULTSThe hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFbeta1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. CONCLUSIONSThese data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFbeta1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype.
Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGF[beta]1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGF[beta]1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGF[beta]1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype.
Introduction Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. Methods We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFI21) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. Results The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFI21 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. Conclusions These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFI21 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype.
Abstract Introduction Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic mice, carrying an additional A form of PR as a transgene, exhibit morphological features associated with the development of mammary tumors. Our objective was to determine the roles of estrogen (E) and progesterone (P) in the genesis of mammary hyperplasias/preneoplasias in PR-A transgenics. Methods We subjected PR-A mice to hormonal treatments and analyzed mammary glands for the presence of hyperplasias and used BrdU incorporation to measure proliferation. Quantitative image analysis was carried out to compare levels of latency-associated peptide and transforming growth factor beta 1 (TGFβ1) between PR-A and PR-B transgenics. Basement membrane disruption was examined by immunofluorescence and proteolytic activity by zymography. Results The hyperplastic phenotype of PR-A transgenics is inhibited by ovariectomy, and is reversed by treatment with E + P. Studies using the antiestrogen ICI 182,780 or antiprogestins RU486 or ZK 98,299 show that the increase in proliferation requires signaling through E/estrogen receptor alpha but is not sufficient to give rise to hyperplasias, whereas signaling through P/PR has little impact on proliferation but is essential for the manifestation of hyperplasias. Increased proliferation is correlated with decreased TGFβ1 activation in the PR-A transgenics. Analysis of basement membrane integrity showed loss of laminin-5, collagen III and collagen IV in mammary glands of PR-A mice, which is restored by ovariectomy. Examination of matrix metalloproteases (MMPs) showed that total levels of MMP-2 correlate with the steady-state levels of PR, and that areas of laminin-5 loss coincide with those of activation of MMP-2 in PR-A transgenics. Activation of MMP-2 is dependent on treatment with E and P in ovariectomized wild-type mice, but is achieved only by treatment with P in PR-A mice. Conclusions These data establish a link between hormonal response, proliferation, modulation of MMP activity and maintenance of basement membrane integrity that depend on a balance in the expression levels of PR-A and PR-B isoforms. Notably, concomitant increased proliferation, due to inhibition of TGFβ1 activation, and loss of basement membrane integrity, via increased MMP-2 activity, appear to be prerequisites for the PR-A hyperplastic phenotype.
ArticleNumber R72
Audience Academic
Author Barcellos-Hoff, Mary Helen
Bissell, Mina J
Shyamala, Gopalan
Simian, Marina
AuthorAffiliation 1 Life Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA
2 Current address: Research Area, Instituto de Oncología 'Ángel H. Roffo', Avda San Martín 5481, Buenos Aires C1417DTB, Argentina
3 Current address: Department of Radiation Oncology, New York University Langone Medical Center, 566 First Avenue, New York, NY 10016, USA
AuthorAffiliation_xml – name: 1 Life Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA
– name: 3 Current address: Department of Radiation Oncology, New York University Langone Medical Center, 566 First Avenue, New York, NY 10016, USA
– name: 2 Current address: Research Area, Instituto de Oncología 'Ángel H. Roffo', Avda San Martín 5481, Buenos Aires C1417DTB, Argentina
Author_xml – sequence: 1
  givenname: Marina
  surname: Simian
  fullname: Simian, Marina
  email: marina.simian@galuzzi.com
  organization: Life Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA. marina.simian@galuzzi.com
– sequence: 2
  givenname: Mina J
  surname: Bissell
  fullname: Bissell, Mina J
– sequence: 3
  givenname: Mary Helen
  surname: Barcellos-Hoff
  fullname: Barcellos-Hoff, Mary Helen
– sequence: 4
  givenname: Gopalan
  surname: Shyamala
  fullname: Shyamala, Gopalan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19788752$$D View this record in MEDLINE/PubMed
BookMark eNp9kkuLFDEQxxtZcR-K30CCgnuaNUl3Hu1BGJZ1FRYUUfAW0unq6SzdSZv0LOzVT26NM-iMqOSQoupX_6Qep8VRiAGK4imjF4xp-apxiVdUPyhOWCXFQlT869GefVyc5nxLKVNa6EfFMauV1krwk-L7VZ5TXEEgNrRk2ph5hoTqJIGDaY4pk97eAWl9nn1wM0lxgEx8IHMPBGnbDD73I4SZxO6ns7-fIE2DxQRHph5CnNGzSfn4abEkc7Ih45MYHL2Dx8XDzg4Znuzus-LL26vPl-8WNx-u318ubxaNLOW8EIK5su1YrSV0jRTS1W1jS1XSTslKaNnoRrSqog5apZjtnGsVt1yAa6ksWXlWvNnqTutmhNbhh5MdzJT8aNO9idabw0jwvVnFO8NVTbXgKPB6K9D4-A-Bw4iLo9lNBpPPd6-n-G2NbTOjzw6GwQaI62xUWbGaK10j-fK_JMex6lpWCD7_A7yN6xSwh4aXknFR6RKhF1toZQcwPnQRv-Y2imbJGeVVLWqK1MVfKDwt4IhwGzqP_oOEXTkuxZwTdL_awKjZrORe4c_22_6b2-1g-QM0weGF
CitedBy_id crossref_primary_10_1016_j_etap_2021_103785
crossref_primary_10_1016_j_mce_2015_09_023
crossref_primary_10_3390_cells9092074
crossref_primary_10_1530_ERC_11_0378
crossref_primary_10_3389_fcell_2020_00415
crossref_primary_10_1186_s12885_018_4550_z
crossref_primary_10_3109_10253890_2011_624223
crossref_primary_10_1016_j_jmb_2016_06_020
crossref_primary_10_1042_EBC20200163
crossref_primary_10_1158_0008_5472_CAN_13_0021
crossref_primary_10_1016_j_jsbmb_2024_106515
Cites_doi 10.1016/0092-8674(95)90199-X
10.1006/mgme.1999.2897
10.1083/jcb.125.3.681
10.1083/jcb.200302090
10.1242/dev.112.2.439
10.1083/jcb.118.5.1271
10.1016/S1071-5576(99)00058-1
10.1146/annurev.bi.63.070194.002315
10.1023/A:1014820500738
10.1101/gad.9.18.2266
10.1016/S0092-8674(03)00432-X
10.1186/bcr65
10.1016/S0002-9440(10)61158-3
10.1177/153537020222701104
10.1083/jcb.148.3.615
10.1023/A:1026339111278
10.1016/0012-1606(83)90086-6
10.1016/S0002-9440(10)62985-9
10.1016/j.tcb.2008.08.007
10.1126/science.1131000
10.1016/S0960-0760(01)00182-0
10.1073/pnas.95.2.696
10.1093/carcin/24.3.403
10.1091/mbc.6.10.1287
10.1016/S0960-0760(97)00128-3
10.1073/pnas.97.7.3044
10.1136/jcp.54.8.624
10.1186/bcr634
10.1016/S0002-9440(10)65589-7
10.1016/S0092-8674(00)81009-0
10.1128/MCB.15.4.1847
ContentType Journal Article
Copyright COPYRIGHT 2009 BioMed Central Ltd.
Copyright National Library of Medicine - MEDLINE Abstracts 2009
Copyright ©2009 Simian et al.; licensee BioMed Central Ltd. 2009 Simian et al.; licensee BioMed Central Ltd.
Copyright_xml – notice: COPYRIGHT 2009 BioMed Central Ltd.
– notice: Copyright National Library of Medicine - MEDLINE Abstracts 2009
– notice: Copyright ©2009 Simian et al.; licensee BioMed Central Ltd. 2009 Simian et al.; licensee BioMed Central Ltd.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
K9.
7QO
8FD
FR3
P64
7X8
5PM
DOI 10.1186/bcr2408
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Health & Medical Complete (Alumni)
Biotechnology Research Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList

ProQuest Health & Medical Complete (Alumni)
MEDLINE
MEDLINE - Academic

Engineering Research Database
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1465-542X
EndPage R72
ExternalDocumentID oai_biomedcentral_com_bcr2408
1933472201
A210249590
10_1186_bcr2408
19788752
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States
Argentina
GeographicLocations_xml – name: Argentina
– name: United States
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: U54CA112970
– fundername: NCI NIH HHS
  grantid: U54CA126552
– fundername: NCI NIH HHS
  grantid: R01 CA129523
– fundername: NCI NIH HHS
  grantid: R01CA057621
– fundername: NCI NIH HHS
  grantid: R01 CA057621-10
– fundername: NCI NIH HHS
  grantid: R01 CA057621
– fundername: NCI NIH HHS
  grantid: 5 R01CA064786
– fundername: NIA NIH HHS
  grantid: R01 AG022413
GroupedDBID ---
04C
0R~
23N
2VQ
2WC
3V.
4.4
53G
5GY
5VS
6J9
7X7
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
ABUWG
ACGFO
ACGFS
ACJQM
ACMJI
ACPRK
ACRMQ
ADBBV
ADFRT
ADINQ
ADUKV
AENEX
AFKRA
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BMSDO
BPHCQ
BVXVI
C1A
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBD
EBLON
EBS
ECM
EIF
EIHBH
EJD
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
HZ~
IAO
ICW
IHR
INH
INR
ITC
KQ8
LGEZI
LOTEE
NADUK
NPM
NXXTH
O5R
O5S
O9-
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
RBZ
ROL
RPM
RSV
SBL
SOJ
TR2
U2A
UKHRP
WOQ
AAYXX
CITATION
AFPKN
K9.
7QO
8FD
FR3
P64
7X8
ABVAZ
AFGXO
AFNRJ
ZA5
5PM
ID FETCH-LOGICAL-b636t-551c3df1986efb656c9dba3730f764586b8b5d740ced771afccd72a25ecd06313
IEDL.DBID RBZ
ISSN 1465-542X
1465-5411
IngestDate Tue Sep 17 21:28:34 EDT 2024
Wed May 22 07:10:52 EDT 2024
Fri Oct 25 03:07:22 EDT 2024
Fri Oct 25 07:50:31 EDT 2024
Thu Oct 10 17:34:41 EDT 2024
Wed Jul 24 18:22:29 EDT 2024
Tue Nov 12 23:37:02 EST 2024
Wed Oct 09 16:48:59 EDT 2024
Tue Oct 15 23:41:40 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b636t-551c3df1986efb656c9dba3730f764586b8b5d740ced771afccd72a25ecd06313
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://dx.doi.org/10.1186/bcr2408
PMID 19788752
PQID 236125483
PQPubID 42565
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2790852
biomedcentral_primary_oai_biomedcentral_com_bcr2408
proquest_miscellaneous_734192789
proquest_miscellaneous_21468964
proquest_journals_236125483
gale_infotracmisc_A210249590
gale_infotracacademiconefile_A210249590
crossref_primary_10_1186_bcr2408
pubmed_primary_19788752
PublicationCentury 2000
PublicationDate 2009-01-01
PublicationDateYYYYMMDD 2009-01-01
PublicationDate_xml – month: 01
  year: 2009
  text: 2009-01-01
  day: 01
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Breast cancer research : BCR
PublicationTitleAlternate Breast Cancer Res
PublicationYear 2009
Publisher BioMed Central Ltd
National Library of Medicine - MEDLINE Abstracts
BioMed Central
Publisher_xml – name: BioMed Central Ltd
– name: National Library of Medicine - MEDLINE Abstracts
– name: BioMed Central
References 7585552 - Cancer Res. 1995 Nov 1;55(21):5063-8
12038707 - Breast Cancer Res Treat. 2002 Mar;72(2):163-72
8521507 - Cell. 1995 Dec 15;83(6):835-9
6852366 - Dev Biol. 1983 Jun;97(2):274-90
7557380 - Genes Dev. 1995 Sep 15;9(18):2266-78
10737785 - Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3044-9
8175886 - J Cell Biol. 1994 May;125(3):681-93
10732327 - J Soc Gynecol Investig. 2000 Jan-Feb;7(1 Suppl):S33-7
11897499 - J Steroid Biochem Mol Biol. 2002 Feb;80(2):137-48
12057913 - Am J Pathol. 2002 Jun;160(6):2081-93
7485387 - Am J Pathol. 1995 Nov;147(5):1228-37
7979245 - Annu Rev Biochem. 1994;63:451-86
12809600 - Cell. 2003 Jun 13;113(6):685-700
10428026 - Cell. 1999 Jul 23;98(2):137-46
12242106 - Biochim Biophys Acta. 2002 Oct 2;1603(1):1-9
9459191 - J Steroid Biochem Mol Biol. 1997 Nov-Dec;63(4-6):251-9
11250717 - Breast Cancer Res. 2000;2(4):252-7
10935020 - J Mammary Gland Biol Neoplasia. 1997 Oct;2(4):323-34
18848450 - Trends Cell Biol. 2008 Nov;18(11):560-74
7891678 - Mol Cell Biol. 1995 Apr;15(4):1847-57
10662785 - J Cell Biol. 2000 Feb 7;148(3):615-24
17038622 - Science. 2006 Oct 13;314(5797):298-300
16049327 - Am J Pathol. 2005 Aug;167(2):409-17
12663498 - Carcinogenesis. 2003 Mar;24(3):403-9
11477119 - J Clin Pathol. 2001 Aug;54(8):624-30
14680479 - Breast Cancer Res. 2004;6(1):1-11
10527668 - Mol Genet Metab. 1999 Oct;68(2):182-90
12975354 - J Cell Biol. 2003 Sep 15;162(6):1123-33
9708806 - Am J Pathol. 1998 Aug;153(2):457-67
1512297 - J Cell Biol. 1992 Sep;118(5):1271-82
9435255 - Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):696-701
1794314 - Development. 1991 Jun;112(2):439-49
8573787 - Mol Biol Cell. 1995 Oct;6(10):1287-303
12486206 - Exp Biol Med (Maywood). 2002 Dec;227(11):969-80
PA Mote (2372_CR34) 2002; 72
WP Bocchinfuso (2372_CR28) 1997; 2
JE Fata (2372_CR10) 2004; 6
MD Sternlicht (2372_CR22) 1999; 98
BS Wiseman (2372_CR26) 2003; 162
WL Kraus (2372_CR12) 1995; 15
PA Mote (2372_CR33) 2001; 54
CM Nelson (2372_CR29) 2006; 314
YC Chou (2372_CR9) 2003; 24
Y Shi (2372_CR15) 2003; 113
G Shyamala (2372_CR7) 2000; 97
G Shyamala (2372_CR3) 1997; 63
JP Lydon (2372_CR4) 1995; 9
N Koshikawa (2372_CR23) 2000; 148
D Medina (2372_CR8) 2002; 1603
CJ Sympson (2372_CR20) 1994; 125
SA Leonhardt (2372_CR24) 2002; 227
RS Talhouk (2372_CR19) 1992; 118
MJ Duffy (2372_CR25) 2000; 2
JM Williams (2372_CR18) 1983; 97
JP Witty (2372_CR27) 1995; 6
G Shyamala (2372_CR6) 1998; 95
JD Graham (2372_CR32) 1995; 55
MJ Tsai (2372_CR2) 1994; 63
G Shyamala (2372_CR5) 1999; 68
BS Katzenellenbogen (2372_CR11) 2000; 7
DJ Mangelsdorf (2372_CR1) 1995; 83
RG Rowe (2372_CR31) 2008; 18
RS Talhouk (2372_CR13) 1991; 112
KB Ewan (2372_CR14) 2005; 167
G Shyamala (2372_CR30) 2002; 80
MH Barcellos-Hoff (2372_CR16) 1995; 147
KB Ewan (2372_CR17) 2002; 160
N Thomasset (2372_CR21) 1998; 153
References_xml – volume: 83
  start-page: 835
  year: 1995
  ident: 2372_CR1
  publication-title: Cell
  doi: 10.1016/0092-8674(95)90199-X
  contributor:
    fullname: DJ Mangelsdorf
– volume: 68
  start-page: 182
  year: 1999
  ident: 2372_CR5
  publication-title: Mol Genet Metab
  doi: 10.1006/mgme.1999.2897
  contributor:
    fullname: G Shyamala
– volume: 125
  start-page: 681
  year: 1994
  ident: 2372_CR20
  publication-title: J Cell Biol
  doi: 10.1083/jcb.125.3.681
  contributor:
    fullname: CJ Sympson
– volume: 162
  start-page: 1123
  year: 2003
  ident: 2372_CR26
  publication-title: J Cell Biol
  doi: 10.1083/jcb.200302090
  contributor:
    fullname: BS Wiseman
– volume: 112
  start-page: 439
  year: 1991
  ident: 2372_CR13
  publication-title: Development
  doi: 10.1242/dev.112.2.439
  contributor:
    fullname: RS Talhouk
– volume: 147
  start-page: 1228
  year: 1995
  ident: 2372_CR16
  publication-title: Am J Pathol
  contributor:
    fullname: MH Barcellos-Hoff
– volume: 118
  start-page: 1271
  year: 1992
  ident: 2372_CR19
  publication-title: J Cell Biol
  doi: 10.1083/jcb.118.5.1271
  contributor:
    fullname: RS Talhouk
– volume: 7
  start-page: S33
  year: 2000
  ident: 2372_CR11
  publication-title: J Soc Gynecol Investig
  doi: 10.1016/S1071-5576(99)00058-1
  contributor:
    fullname: BS Katzenellenbogen
– volume: 63
  start-page: 451
  year: 1994
  ident: 2372_CR2
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev.bi.63.070194.002315
  contributor:
    fullname: MJ Tsai
– volume: 55
  start-page: 5063
  year: 1995
  ident: 2372_CR32
  publication-title: Cancer Res
  contributor:
    fullname: JD Graham
– volume: 72
  start-page: 163
  year: 2002
  ident: 2372_CR34
  publication-title: Breast Cancer Res Treat
  doi: 10.1023/A:1014820500738
  contributor:
    fullname: PA Mote
– volume: 9
  start-page: 2266
  year: 1995
  ident: 2372_CR4
  publication-title: Genes Dev
  doi: 10.1101/gad.9.18.2266
  contributor:
    fullname: JP Lydon
– volume: 113
  start-page: 685
  year: 2003
  ident: 2372_CR15
  publication-title: Cell
  doi: 10.1016/S0092-8674(03)00432-X
  contributor:
    fullname: Y Shi
– volume: 2
  start-page: 252
  year: 2000
  ident: 2372_CR25
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr65
  contributor:
    fullname: MJ Duffy
– volume: 160
  start-page: 2081
  year: 2002
  ident: 2372_CR17
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)61158-3
  contributor:
    fullname: KB Ewan
– volume: 227
  start-page: 969
  year: 2002
  ident: 2372_CR24
  publication-title: Exp Biol Med (Maywood)
  doi: 10.1177/153537020222701104
  contributor:
    fullname: SA Leonhardt
– volume: 148
  start-page: 615
  year: 2000
  ident: 2372_CR23
  publication-title: J Cell Biol
  doi: 10.1083/jcb.148.3.615
  contributor:
    fullname: N Koshikawa
– volume: 2
  start-page: 323
  year: 1997
  ident: 2372_CR28
  publication-title: J Mammary Gland Biol Neoplasia
  doi: 10.1023/A:1026339111278
  contributor:
    fullname: WP Bocchinfuso
– volume: 97
  start-page: 274
  year: 1983
  ident: 2372_CR18
  publication-title: Dev Biol
  doi: 10.1016/0012-1606(83)90086-6
  contributor:
    fullname: JM Williams
– volume: 1603
  start-page: 1
  year: 2002
  ident: 2372_CR8
  publication-title: Biochim Biophys Acta
  contributor:
    fullname: D Medina
– volume: 167
  start-page: 409
  year: 2005
  ident: 2372_CR14
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)62985-9
  contributor:
    fullname: KB Ewan
– volume: 18
  start-page: 560
  year: 2008
  ident: 2372_CR31
  publication-title: Trends in Cell Biology
  doi: 10.1016/j.tcb.2008.08.007
  contributor:
    fullname: RG Rowe
– volume: 314
  start-page: 298
  year: 2006
  ident: 2372_CR29
  publication-title: Science
  doi: 10.1126/science.1131000
  contributor:
    fullname: CM Nelson
– volume: 80
  start-page: 137
  year: 2002
  ident: 2372_CR30
  publication-title: J Steroid Biochem Mol Biol
  doi: 10.1016/S0960-0760(01)00182-0
  contributor:
    fullname: G Shyamala
– volume: 95
  start-page: 696
  year: 1998
  ident: 2372_CR6
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.95.2.696
  contributor:
    fullname: G Shyamala
– volume: 24
  start-page: 403
  year: 2003
  ident: 2372_CR9
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/24.3.403
  contributor:
    fullname: YC Chou
– volume: 6
  start-page: 1287
  year: 1995
  ident: 2372_CR27
  publication-title: Mol Biol Cell
  doi: 10.1091/mbc.6.10.1287
  contributor:
    fullname: JP Witty
– volume: 63
  start-page: 251
  year: 1997
  ident: 2372_CR3
  publication-title: J Steroid Biochem Mol Biol
  doi: 10.1016/S0960-0760(97)00128-3
  contributor:
    fullname: G Shyamala
– volume: 97
  start-page: 3044
  year: 2000
  ident: 2372_CR7
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.97.7.3044
  contributor:
    fullname: G Shyamala
– volume: 54
  start-page: 624
  year: 2001
  ident: 2372_CR33
  publication-title: J Clin Pathol
  doi: 10.1136/jcp.54.8.624
  contributor:
    fullname: PA Mote
– volume: 6
  start-page: 1
  year: 2004
  ident: 2372_CR10
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr634
  contributor:
    fullname: JE Fata
– volume: 153
  start-page: 457
  year: 1998
  ident: 2372_CR21
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)65589-7
  contributor:
    fullname: N Thomasset
– volume: 98
  start-page: 137
  year: 1999
  ident: 2372_CR22
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)81009-0
  contributor:
    fullname: MD Sternlicht
– volume: 15
  start-page: 1847
  year: 1995
  ident: 2372_CR12
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.15.4.1847
  contributor:
    fullname: WL Kraus
SSID ssj0017858
Score 2.0265913
Snippet Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A transgenic...
Abstract Introduction Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands...
Introduction Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A...
INTRODUCTIONExpression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A...
INTRODUCTION: Expression of the A and B forms of progesterone receptor (PR) in an appropriate ratio is critical for mammary development. Mammary glands of PR-A...
SourceID pubmedcentral
biomedcentral
proquest
gale
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage R72
SubjectTerms Animals
Breast cancer
Development and progression
Estradiol - pharmacology
Estrogen
Genetic aspects
Hormone receptors
Hyperplasia
Mammary Glands, Animal - drug effects
Mammary Glands, Animal - pathology
Mice
Mice, Transgenic
Physiological aspects
Progesterone
Progesterone - pharmacology
Receptors, Estrogen - physiology
Receptors, Progesterone - genetics
Receptors, Progesterone - physiology
Research article
Risk factors
SummonAdditionalLinks – databaseName: PubMed Central
  dbid: RPM
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCbaHoZdhq3dw2u36TBsJzfxQw8fg6JFMSBDMaxAb4b1MBKgkYPELbDrfvlI2WmrAbvsGpKIZJESSX2kAD5bWxVZW7q0kVqnJTdtqgulU0WZfMHzRoXXGubfxeV1-e2G3-wB39XCBNC-0ctTf7s69ctFwFauV2ayw4lNruZnuazQU8gn-7CPCroL0cerA6nCo5y4A_CUl1k2VMqiHy0m2myoo1doFEooOqo2isrcb6PT6e89-skhFQMon5xIFy_hxehKstkw5Few5_whHM08htGrX-wLC-DOkDU_hGfz8Q79CH6fb_tNh3rDGm8Z4bNCs4TOO4a7n1vT8zts0dw7Zsn-vekZQRC3bOkZeosMuZuQuqK8Iuva8OMCw9nNGj1xHAsj2FhHuV0SufqRzlhPJyL-JRJXuDO9huuL859nl-n4EkOqRSH6FN0qU9g2q5RwrUYX0FRWNwV-_FaKkiuhleZWllPjrJRZ0xpjZd7k3BmLPlBWvIEDj_N4B2zaZtqhAmRGK-JXhctLYx1XrlIYnCVQRCtSr4euGzX1wY4paJL1uKQJsN26PQiE8EaJR5avtJ41GS6Km2asP8BhUQusekbBL4aL1TSBk4gTDc5E5OOdRtSjwW9r6mGDsbYqEvj0QCVBwrB5190hC1W5VQJnyP7BIam5HpUmJ_B2ULDHyYwKm4CMVC_6PDEFrSe0Cx-t5f1_Sx7D8-EOjRJPJ3DQb-7cB3TFev0xmN4fMXA5Xg
  priority: 500
  providerName: National Library of Medicine
Title Estrogen and progesterone receptors have distinct roles in the establishment of the hyperplastic phenotype in PR-A transgenic mice
URI https://www.ncbi.nlm.nih.gov/pubmed/19788752
https://www.proquest.com/docview/236125483
https://search.proquest.com/docview/21468964
https://search.proquest.com/docview/734192789
http://dx.doi.org/10.1186/bcr2408
https://pubmed.ncbi.nlm.nih.gov/PMC2790852
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1da9RAcKgVxJeirdrYeq4g-rR4yWY_8ngtLUWoiFgovoTsR7iCJsddWuirv9yZTXq9FH3xNTNDdnd2dmdm5wPgvfeFSOs88Epby3Ppam6FsdyQJ1_JrDKxW8P5F3V2kX--lJdb8O7vL_ipUZ-sW1IZrkfwOKNKKmSQH_1YPxRoE1tworxLLvM07fNiNwkfZLL_HF1AD4_hjXtoHCO5cemcPoOdQVtks569z2ErNLuwN2vQUv51yz6wGL8ZHeO78OR8eCbfg98nq27Z4tZgVeMZhWDFeghtExgecGFBHXbYvLoJzJOIN65jFGW4YlcNQ4WQIXYVvVPkOmRtHT_O0WJdLlDZxrEwigxryX1LJF-_8Rnr6NLDXyKQOty_gIvTk-_HZ3xotsCtEqrjqDk54eu0MCrUFrU8V3hbCTwAaq1yaZQ1VnqdT13wWqdV7ZzXWZXJ4DyqOal4CdsNzmMf2LRObUAep84awjciZLnzQZpQGLS_EhAjjpSLvrBGSaWuxxCUunLgYwLsjm9rgmjBGHWP8pH4WZJsIrmrhhQDHBZVuSpnZN-iRVhMEzgcYaJMuRH44G5HlINMr0oqU4PmtBEJvF1DiZDC1JrQXiMKJbIVCmfI_oGhqX4eZR8n8KrfYPeTKSiyU2YJ6NHWGy3PGNJczWNF8EwXqDpnr_9rYQ_gaf9ERn6lQ9jultfhDWpanZ1ED8UkStwkOsL-AN1AMKc
link.rule.ids 108,230,315,730,783,787,867,888,24949,27936,27937,53804,53806,76140,76141
linkProvider BioMedCentral
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbtRAzCpFgl4QtDxCWzoHBKfA5jGPHBfUskC3QlUrVVyizCPaSm2yyqaVuPLl2JPsdlOJS69rWzuTsT22xw-A99ZmSVSmLiyk1mHKTRnqROlQUSRf8LhQflrD9ERMztMfF_xiA74ta2F0042swR03fbub2af1SvQrr76XWWOd0CvxWZuGmnU9gsfol6ckoadffq-eE6TygzpRK_CQp1HUVc-uE96rd78aXFP3lfXabTXMpFy7mo6ew7PepmTjbrUvYMNV27AzrtCfvv7DPjCf5enD59vwZNo_pu_A38NF29TIQKyoLKNELd81oa4cQzXo5jSHh82KW8csKYLKtIxyERfssmJoNjLELnwMiwKMrC79jzP0a5s5muS4Fkb5YzUFeYnk12k4Zi1djfiXCLxGFfUSzo8Oz75Own4kQ6hFItoQ7SuT2DLKlHClRlvQZFYXCaqJUoqUK6GV5lamI-OslFFRGmNlXMTcGYvGUJS8gs0K9_EG2KiMtENOiIxWhK8SF6fGOq5cptBLCyAZnEg-79pv5NQQewhBjsj7cwyALc9tReD9HCXuUD7SeeYkwUhuir4QAZdFvbDyMXnB6DdmowD2BpgoeWYA3l1yRN5L_iKnZjbodKskgIMVlAgpma1y9Q2iULlbJnCH7D8YkrrsUY1yAK87BrvbTEb5nzwOQA5Yb_B5hpDqcub7hscyQwM7fvugD3sATydn0-P8-PvJz13Y6h7VKBK1B5ttc-P20TZr9Tsvd_8AsChBFA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbtRAzCpFqrggaIGmLXQOCE6hm8c8clygq-XRqqqoVHGJMo9oK9pklU0rceXLsSfZ7aYSF25R7FEyM7bH9vgB8NbaLInK1IWF1DpMuSlDnSgdKvLkCx4XyndrODkV04v06yW_3IDpMhdGN13LGpxx05e7mX1Yz0S_9uIbH8yvo7ktO65X4kibhqp1PYLHaJin1MTh_OPP1X2CVL5TJ4oFHvI0irr02fWBDxLerwfn1ENpvXZcDUMp186myTN42iuVbNxRwXPYcNU27IwrNKhvfrN3zId5ev_5Nmyd9LfpO_DneNE2NVIQKyrLKFLLl02oK8dQDro5NeJhs-LOMUuSoDIto2DEBbuqGOqNDLEL78QiDyOrS_9yhoZtM0edHP-FUQBZTV5eGnJ2Ho5ZS2cjfhKBNyijXsDF5PjHp2nY92QItUhEG6KCZRJbRpkSrtSoDJrM6iJBOVFKkXIltNLcynRknJUyKkpjrIyLmDtjURuKkpewWeE8doGNykg7JIXIaEX4KnFxaqzjymUKzbQAksGO5POu_kZOFbGHECSJvN_HANhy31YDvKGjxD3Ke9rPnFiYCKnoMxHwt6gYVj4mMxgNx2wUwMEAE1nPDMD7S4rIe9Zf5FTNBq1ulQRwuILSQIpmq1x9iyiU75YJnCH7B4akMnuUpBzAq47A7ieTUQAojwOQA9IbLM8QUl3NfOHwWGaoYcd7_7Wwh7B19nmSf_9y-m0fnnSXauSJOoDNtrl1r1E3a_Ubz3Z_AReYQN8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Estrogen+and+progesterone+receptors+have+distinct+roles+in+the+establishment+of+the+hyperplastic+phenotype+in+PR-A+transgenic+mice&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Simian%2C+Marina&rft.au=Bissell%2C+Mina&rft.au=Barcellos-Hoff%2C+Mary&rft.au=Shyamala%2C+Gopalan&rft.date=2009-01-01&rft.pub=BioMed+Central+Ltd&rft.issn=1465-5411&rft.eissn=1465-542X&rft.volume=11&rft.issue=5&rft.spage=R72&rft.epage=R72&rft_id=info:doi/10.1186%2Fbcr2408&rft.externalDBID=n%2Fa&rft.externalDocID=oai_biomedcentral_com_bcr2408
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon